Moving the trials overseas has never been explained but the advantages that Anavex has enjoyed, including tax rebates, have worked out financially for them.
It seems to be a favorable environment and I hope they are inclined to act responsively to the data that the trials are producing.
It would be in Australia’s best interest to make a decision soon if they want to help their suffering people.